Company: SMNR
Filing Date: 2025-07-23
Form Type: S-4/A
Source: 0001193125-25-163401
Chunk: 73

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-23
Form: S-4/A
Chunk 73
---
 When and where is the Meeting? |

| A: | The Meeting will be held on        , 2025 at        , Eastern Time, at the offices of US Tiger Securities, Inc. located at 437 Madison Avenue, 27th Floor, New York, New York 10022. |

| Q: | What is being voted on at the Meeting? |

| A: | Below are the Proposals that the Denali shareholders are being asked to vote on at the Meeting: |

| • |     | Proposal 1 — The Business Combination Proposal — to approve and adopt the Merger Agreement and the Business Combination. |

| • |     | Proposal 2 — The Domestication Proposal — to approve the domestication of Denali as a Delaware corporation. |

| • |     | Proposal 3 — The Charter Approval Proposal — to approve and adopt the Proposed Charter attached to this proxy statement/prospectus as Annex B. |

| • |     | Proposal 4 — The Bylaws Approval Proposal — to approve and adopt the Proposed Bylaws attached to this proxy statement/prospectus as Annex C. |

| • |     | Proposals 5A-5G — The Advisory Governance Proposals — to approve and adopt, on a non-binding advisory basis, a proposal to approve governance provisions contained in the Proposed Charter, as compared to our Current Denali Charter. |

| • |     | Proposal 6 — The Director Election Proposal — to elect, effective as of the consummation of the Business Combination, Jaisim Shah, Henry Ji, Ph.D., Jay Chun, M.D., Ph.D., Dorman Followwill and |

24

| Yue Alexander Wu, Ph.D. to serve on the New Semnur Board until their respective successors are duly elected and qualified. |

| • |     | Proposal 7 —  The Nasdaq Proposal — to approve and adopt the issuance of more than 20% of the issued and outstanding Denali Ordinary Shares in connection with the terms of the Merger Agreement, which will result in a change of control, as required by Nasdaq Listing Rule 5635(a) and (